Acetazolamide
- Generic Name
- Acetazolamide
- Drug Type
- Small Molecule
- Chemical Formula
- C4H6N4O3S2
- CAS Number
- 59-66-5
- Unique Ingredient Identifier
- O3FX965V0I
- Background
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
- Indication
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
- Associated Conditions
- Acute angle-closure glaucoma, Edema, Familial periodic paralysis, Generalized Tonic-Clonic Seizures, Metabolic Alkalosis, Open Angle Glaucoma (OAG), Other and unspecified effects of high altitude, Cystine renal calculi, Drug-induced edema, Nonuveitic secondary glaucoma, Salicylate intoxication
- Associated Therapies
- Urine alkalinization therapy
Rescue Pharmacotherapy for OSA
- Conditions
- Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05293600
- Locations
- 🇺🇸
Sleep Disorders Research Program Brigham and Women's Hospital, Boston, Massachusetts, United States
Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions
- Conditions
- Macular Edema
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT05290948
- Locations
- 🇮🇷
Ophthalmic Research center, Tehran, Iran, Islamic Republic of
Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide
- Conditions
- Acute Mountain Sickness
- Interventions
- Device: Doctormate® (twice daily for 6 days)Device: Doctormate® (forth daily for 3 days)
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Ji Xunming,MD,PhD
- Target Recruit Count
- 252
- Registration Number
- NCT05023941
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
Acetazolamide Trial in Normal Pressure Hydrocephalus
- Conditions
- Idiopathic Normal Pressure Hydrocephalus (INPH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Uppsala University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04975269
- Locations
- 🇸🇪
Department of Clinical Neurophysiology, Neurosurgery and Neurology, Uppsala University Hospital, Uppsala, Sweden
Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude
- Conditions
- Altitude SicknessRight Heart FunctionChronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 100
- Registration Number
- NCT04915365
- Locations
- 🇰🇬
National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD
- Conditions
- Altitude SicknessChronic Obstructive Pulmonary DiseaseAltitude Hypoxia
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 100
- Registration Number
- NCT04913389
- Locations
- 🇰🇬
National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Acetazolamide for Treatment Resistant Schizophrenia
- Conditions
- SchizophreniaSchizo Affective Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Vishwajit Nimgaonkar, MD PhD
- Target Recruit Count
- 60
- Registration Number
- NCT04887792
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇮🇳St John's Medical College Hospital, Bangalore, India
Optimal Dosage of Acetazolamide for OSA Treatment
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- University Hospital, Antwerp
- Target Recruit Count
- 100
- Registration Number
- NCT04726982
- Locations
- 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium
Acetazolamide Efficacy in Ataxia in PMM2-CDG
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT04679389
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
- Conditions
- OSAObstructive Sleep Apnea
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT04639193
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
🇺🇸UCSD Health - Pulmonary and Sleep Clinic, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.